Equities research analysts expect Rocket Pharmaceuticals Inc (NASDAQ:RCKT) to announce earnings of ($0.52) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Rocket Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.69) and the highest is ($0.40). Rocket Pharmaceuticals posted earnings per share of ($0.66) in the same quarter last year, which indicates a positive year-over-year growth rate of 21.2%. The business is expected to announce its next quarterly earnings report on Thursday, March 5th.
On average, analysts expect that Rocket Pharmaceuticals will report full-year earnings of ($1.68) per share for the current year, with EPS estimates ranging from ($1.89) to ($1.54). For the next financial year, analysts forecast that the business will report earnings of ($2.28) per share, with EPS estimates ranging from ($3.45) to ($1.57). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Rocket Pharmaceuticals.
Rocket Pharmaceuticals (NASDAQ:RCKT) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.11.
Rocket Pharmaceuticals stock traded up $2.65 during trading hours on Friday, hitting $22.37. The stock had a trading volume of 1,002,018 shares, compared to its average volume of 242,551. Rocket Pharmaceuticals has a 1-year low of $10.75 and a 1-year high of $24.42. The stock has a market capitalization of $992.91 million, a price-to-earnings ratio of -11.83 and a beta of 2.78. The stock’s fifty day moving average is $15.56 and its two-hundred day moving average is $13.98. The company has a debt-to-equity ratio of 0.20, a current ratio of 11.07 and a quick ratio of 11.07.
Several large investors have recently modified their holdings of RCKT. Metropolitan Life Insurance Co NY grew its stake in shares of Rocket Pharmaceuticals by 43.4% in the third quarter. Metropolitan Life Insurance Co NY now owns 10,616 shares of the biotechnology company’s stock worth $124,000 after acquiring an additional 3,213 shares during the last quarter. Eventide Asset Management LLC raised its stake in shares of Rocket Pharmaceuticals by 42.3% during the third quarter. Eventide Asset Management LLC now owns 1,415,000 shares of the biotechnology company’s stock worth $16,485,000 after buying an additional 420,686 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Rocket Pharmaceuticals by 1,107.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 4,250 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 3,898 shares during the last quarter. Comerica Bank raised its position in shares of Rocket Pharmaceuticals by 35.2% during the 3rd quarter. Comerica Bank now owns 28,155 shares of the biotechnology company’s stock valued at $363,000 after acquiring an additional 7,329 shares during the last quarter. Finally, California Public Employees Retirement System acquired a new stake in shares of Rocket Pharmaceuticals during the third quarter worth $168,000. Institutional investors and hedge funds own 93.86% of the company’s stock.
Rocket Pharmaceuticals Company Profile
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption.
See Also: How to calculate compound interest
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.